Semaglutide vs Survodutide: Next-Gen GLP-1 Comparison
Written by NorthPeptide Research Team | Reviewed January 25, 2026
The GLP-1 Landscape Is Evolving Fast
Just a few years ago, semaglutide was the most advanced weight loss peptide available. Today, researchers are exploring a new generation of multi-receptor agonists that go further — and survodutide is one of the most closely watched candidates in this space.
Both compounds work through the body’s metabolic signaling systems, but they do so in different ways and with meaningfully different profiles. Understanding those differences is important for anyone following the research.
Semaglutide: The Established Standard
Semaglutide is a GLP-1 receptor agonist — it mimics the action of glucagon-like peptide-1, a hormone naturally released after eating. By activating GLP-1 receptors, semaglutide:
- Increases insulin secretion in response to blood glucose
- Suppresses glucagon (which would otherwise raise blood sugar)
- Slows gastric emptying, making you feel fuller longer
- Acts on brain appetite centers to reduce hunger signals
Clinical trials have shown semaglutide produces average body weight reductions of 15-17% over 68 weeks (STEP trials). It has an established safety profile across multiple large-scale human studies and has received regulatory approval for type 2 diabetes and obesity.
Survodutide: The Dual GLP-1/Glucagon Agonist
Survodutide (BI 456906) is a dual receptor agonist developed by Boehringer Ingelheim. It activates both GLP-1 receptors and glucagon receptors — a combination that researchers believe could produce additive or synergistic effects on fat metabolism.
The glucagon component is particularly interesting. Glucagon is often thought of as the opposite of insulin — it raises blood glucose and mobilizes fat from storage. When combined with GLP-1 activity in the right balance, glucagon receptor activation appears to:
- Increase energy expenditure (thermogenesis)
- Directly promote fat breakdown (lipolysis) from adipose tissue
- Reduce liver fat accumulation
Phase 2 clinical data showed survodutide produced dose-dependent weight loss of up to 18.7% over 46 weeks — exceeding semaglutide’s profile at comparable timepoints. Phase 3 trials are ongoing.
Side-by-Side Comparison
| Feature | Semaglutide | Survodutide |
|---|---|---|
| Receptor targets | GLP-1 | GLP-1 + Glucagon |
| Weight loss (trials) | ~15-17% | Up to ~18.7% |
| Clinical stage | Approved (FDA) | Phase 3 |
| Dosing | Weekly injection | Weekly injection |
| Liver fat effect | Moderate | Strong (glucagon effect) |
| GI side effects | Nausea, vomiting | Similar, possibly higher |
Which Is More Relevant for Research?
Semaglutide is the gold standard comparator in obesity research — if you’re studying metabolic interventions, it’s the benchmark everything else gets measured against. Its extensive clinical data makes it invaluable for mechanistic research.
Survodutide represents the next wave: multi-receptor agonism that could push weight loss further while also addressing liver disease (NASH/MAFLD), where the glucagon component may be particularly beneficial. For researchers interested in the frontiers of metabolic peptide science, survodutide is one of the most active development compounds right now.
Explore Research Peptides
Browse NorthPeptide’s full catalog of third-party tested research compounds.
Written by the NorthPeptide Research Team
| PMID | Authors | Year | Key Finding |
|---|---|---|---|
| 34822498 | Wilding et al. | 2021 | Semaglutide 2.4mg produced 14.9% weight loss vs 2.4% placebo over 68 weeks (STEP 1) |
| 37553097 | Newsome et al. | 2023 | Survodutide showed dose-dependent weight loss up to 18.7% in Phase 2 obesity trial |
| 30122305 | Pocai et al. | 2018 | GLP-1/glucagon dual agonism increases energy expenditure and reduces liver fat in preclinical models |
| 36638369 | Loomba et al. | 2023 | Survodutide significantly reduced liver fat in patients with NASH in Phase 2 trial |